Proposed Project Scope

Brentuximab vedotin as part of BrECADD for newly diagnosed Hodgkin Lymphoma

Date: May 2025

Background and Rationale

CDA-AMC received a request from public drug programs for a Non-Sponsored Reimbursement Review of brentuximab vedotin as part of BrECADD for newly diagnosed Hodgkin Lymphoma.

Table I: Policy Questions

Item	Policy Question
1	Should brentuximab vedotin be publicly reimbursed with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) for newly diagnosed Hodgkin Lymphoma (HL)?

Table II: Products Available in Canada

Product	Manufacturer
Brentuximab vedotin	n/a

Project Description

Table III: Project Scope

Criteria	Description
Population	Adult patients with newly diagnosed, advanced-stage, classical HL
Intervention(s)	BrECADD
Comparators	eBEACOPP; nivolumab + AVD; BV-AVD; ABVD
Outcomes	Progression-free survival, treatment-related morbidity, complete response rate, overall survival, adverse events, gonadal toxicity and function, second primary malignancies, event-free survival, quality of life.

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of brentuximab vedotin as part of BrECADD for newly diagnosed HL?
2	What are the harms associated with brentuximab vedotin as part of BrECADD for newly diagnosed HL?
3	What is the expected cost of brentuximab vedotin as part of BrECADD for newly diagnosed HL vs. other reimbursed regimes?

Key Project and Protocol Components

This project will follow the Procedures for Non-Sponsored Reimbursement Reviews.

Status of the Document

This proposed project scope is being posted for information.